| Literature DB >> 20430928 |
J Kievit1, M Krukerink, P J Marang-van de Mheen.
Abstract
BACKGROUND: In The Netherlands, health professionals have created a doctor-driven standardised system to report and analyse adverse outcomes (AO). The aim is to improve healthcare by learning from past experiences. The key elements of this system are (1) an unequivocal definition of an adverse outcome, (2) appropriate contextual information and (3) a three-dimensional hierarchical classification system.Entities:
Mesh:
Year: 2010 PMID: 20430928 PMCID: PMC3002840 DOI: 10.1136/qshc.2008.027458
Source DB: PubMed Journal: Qual Saf Health Care ISSN: 1475-3898
The four main questions that guide weekly discussions on adverse outcomes
1. What are consequences for patient and care? Severity (four-level scale)—intensity and cost of care |
2. What is the complication's main determinant? Targeted disease/co-morbidity/surgery/treatment otherwise |
3. In retrospect; could it have been avoided and how? By other treatment choice/execution/pre-care or after-care/… If so, then why was this not done? Because of pros and cons of alternatives/risk assessment/simply “wrong” |
4. Prospectively: what is the lesson learnt? There is none; the complication is “all in the game” Then what was the risk? |
5. Did the patient know, and how do we know he/she did? Yes, there is a “Lesson”! Then what precisely went wrong, and what should be corrected for the future, how, when and by whom? |
Data on patient admissions for surgery, operations and adverse outcomes (Leiden University Medical Centre, 1997–2005)
| Year | Admissions | Age | Women (%) | ASA at surgery ≥3 (%) | Surgical complexity ≥5 (%) | Admissions with ≥1 adverse outcome | ||
| Mean (SD) | n | % | % | |||||
| 1997 | 2315 | 47.3 (20.8) | 48.2 | 14.6 | 30.3 | 343 | 14.7 | 15.8 |
| 1998 | 2203 | 46.7 (21.2) | 49.2 | 15.4 | 26.2 | 332 | 15.1 | |
| 1999 | 2059 | 45.9 (21.5) | 46.8 | 15.3 | 27.3 | 361 | 17.5 | |
| 2000 | 2008 | 47.6 (21.4) | 46.3 | 20.7 | 30.2 | 368 | 18.3 | 17.3 |
| 2001 | 1906 | 47.1 (21.9) | 49.2 | 21.2 | 31.0 | 317 | 16.6 | |
| 2002 | 2196 | 46.0 (22.7) | 46.7 | 20.7 | 31.2 | 373 | 17.0 | |
| 2003 | 2173 | 45.7 (22.8) | 46.3 | 22.4 | 29.9 | 417 | 19.2 | 21.3 |
| 2004 | 2467 | 46.0 (22.2) | 46.4 | 20.8 | 30.1 | 517 | 21.0 | |
| 2005 | 2580 | 47.8 (22.2) | 48.4 | 16.5 | 32.2 | 603 | 23.4 | |
| All | 19 907 | 46.7 (21.9) | 47.5 | 18.5 | 29.9 | 3631 | 18.2 | |
Incidence of registered adverse outcomes in surgical patients over time
| Variable | OR (99% CI) |
| Year of discharge (reference=1997, with OR 1.00) | |
| 1998 | 1.05 (0.84 to 1.32) |
| 1999 | |
| 2000 | 1.21 (0.97 to 1.52) |
| 2001 | 1.05 (0.84 to 1.33) |
| 2002 | 1.13 (0.91 to 1.42) |
| 2003 | |
| 2004 | |
| 2005 | |
| Age (per life-year) | |
| Gender (female/male) | |
| ASA class | |
| ASA class 3-5 | |
| ASA class missing | |
| High surgical complexity | |
ASA, American Society of Anesthesiologists.
Model fit: Nagelkerke R2=0.171.
Significant differences (p<0.01) are indicated in bold.
Reference: ASA class 1–2.
Severity of adverse outcome in three periods (1997–1999, 2000–2002 and 2003–2005)
| Severity category | 2000–2002 vs 1997–1999, OR (99% CI) | 2003–2005 vs 1997–1999, OR (99% CI) | Per cent of total number of adverse outcomes |
| 1 Temporary health disadvantage, recovery without (re)operation | 0.98 (0.86 to 1.12) | ||
| 2 Recovery after (re)operation | 1.13 (0.93 to 1.38) | 1.16 (0.96 to 1.41) | 21.6 |
| 3 (Probably) permanent damage or function loss | 1.28 (0.84 to 1.94) | 1.36 (0.91 to 2.03) | 3.1 |
| 4 Death | |||
| All adverse outcomes | 1.03 (0.90 to 1.17) | 100 |
In this table, and in tables 5–7, results were adjusted for age, sex, American Society of Anesthesiologists classification and surgical complexity. All ORs are provided with 99% CI (99% CI). Groups of adverse outcomes that changed significantly (p<0.01) over time and contributed more than 5% to the overall incidence are indicated in bold.
Type of adverse outcome in three periods (1997–1999, 2000–2002 and 2003–2005)*
| Type category | 2000–2002 vs 1997–1999, OR (99% CI) | 2003–2005 vs 1997–1999, OR (99% CI) | Per cent of total number of adverse outcomes |
| Rejection/allergy/other immunological reaction | 1.68 (0.88 to 3.23) | 2.03 (1.09 to 3.76) | 1.3 |
| Bleeding/haematoma | 0.79 (0.60 to 1.05) | 0.90 (0.69 to 1.17) | 7.4 |
| Pressure sore | 0.88 (0.44 to 1.74) | 0.92 (0.48 to 1.77) | 1.1 |
| Fistula | 2.06 (0.93 to 4.55) | 2.41 (1.13 to 5.12) | 1.3 |
| Functional disorder | 0.97 (0.80 to 1.18) | ||
| Ischaemia | 1.15 (0.61 to 2.16) | 1.54 (0.86 to 2.76) | 1.3 |
| Symptoms without diagnosis | 1.52 (1.03 to 2.25) | 2.27 (1.58 to 3.25) | 4.4 |
| Injury by mechanical/physical–chemical cause | 0.97 (0.71 to 1.34) | 1.16 (0.86 to 1.56) | 5.0 |
| Necrosis/Infarction | 1.63 (1.11 to 2.40) | 1.21 (0.82 to 1.79) | 3.8 |
| Inflammation/infection | 1.05 (0.89 to 1.25) | ||
| Psychological disturbance | 2.03 (1.18 to 3.46) | 2.32 (1.39 to 3.89) | 2.2 |
| Procedure with specified unintended substandard outcome | 0.35 (0.14 to 0.86) | 0.48 (0.22 to 1.03) | 0.7 |
| Shock | 0.94 (0.69 to 1.28) | 1.04 (0.77 to 1.40) | 5.1 |
| Thrombosis/embolus | 1.20 (0.78 to 1.85) | 1.30 (0.86 to 1.97) | 2.4 |
| Accumulation/leakage of body fluids | 1.01 (0.75 to 1.36) | 1.26 (0.95 to 1.66) | 6.2 |
| Wound healing | 1.34 (0.93 to 1.95) | 1.38 (0.96 to 1.98) | 3.9 |
| Other/non-specified | 0.71 (0.47 to 1.05) | 0.94 (0.65 to 1.34) | 2.2 |
| All adverse outcomes | 1.03 (0.90 to 1.17) | 100 |
The main contributing groups of adverse outcomes are analysed further by localisation (tables 6 and 7).
Body regions with infections in three periods (1997–1999, 2000–2002 and 2003–2005)
| Region of infection | 2000–2002 vs 1997–1999 OR (99% CI) | 2003–2005 vs 1997–1999 OR (99% CI) | Per cent of total number of infections |
| Head | 1.26 (0.42 to 3.74) | 1.67 (0.61 to 4.56) | 1.6 |
| Neck | 2.02 (0.56 to 7.36) | 3.37 (1.03 to 11.00) | 1.5 |
| Back | 1.79 (0.19 to 16.79) | 1.18 (0.11 to 12.51) | 0.3 |
| Thorax | 1.02 (0.74 to 1.40) | 1.11 (0.82 to 1.50) | 18.0 |
| Abdomen | 1.19 (0.90 to 1.58) | ||
| Pelvis | 0.91 (0.67 to 1.24) | 1.22 (0.92 to 1.60) | 20.0 |
| Arm | 1.46 (0.55 to 3.87) | 1.81 (0.73 to 4.51) | 1.9 |
| Leg | 1.40 (0.84 to 2.34) | ||
| Other/non-specified | 0.98 (0.70 to 1.38) | 1.05 (0.76 to 1.45) | 18.2 |
| All infections | 1.05 (0.89 to 1.25) | 100 |
Organ systems with infections in three periods (1997–1999, 2000–2002 and 2003–2005)
| Organ system of infection | 2000–2002 vs 1997–1999, OR (99% CI) | 2003–2005 vs 1997–1999, OR (99% CI) | Per cent of total number of infections |
| Vestibulocochlear organ | – | 0.45 (0.02 to 10.77) | 0.1 |
| Circulatory tract | 1.24 (0.81 to 1.89) | ||
| Digestive tract | 1.12 (0.70 to 1.81) | 0.99 (0.62 to 1.60) | 7.0 |
| Endocrine system | – | – | 0.1 |
| Genital tract | 0.94 (0.26 to 3.43) | 1.42 (0.45 to 4.48) | 1.0 |
| Skin/subcutis (including breast) | 1.72 (0.97 to 3.04) | 1.32 (0.73 to 2.36) | 5.0 |
| Nervous system | 1.14 (0.16 to 8.19) | 0.98 (0.14 to 7.08) | 0.4 |
| Visual system | 1.15 (0.16 to 8.30) | 0.49 (0.05 to 5.17) | 0.3 |
| Respiratory tract | 1.06 (0.75 to 1.50) | 1.21 (0.87 to 1.68) | 14.9 |
| Urinary tract | 0.74 (0.53 to 1.05) | 1.08 (0.80 to 1.46) | 15.4 |
| Other/non-specified tract | 1.23 (0.96 to 1.56) | ||
| All infections | 1.05 (0.89 to 1.25) | 100 |